Capricor Therapeutics Inc.

3 months ago · benzinga.com

Capricor Therapeutics Inc. (NASDAQ:CAPR) stock is trading lower on Monday.

3 months ago · benzinga.com

‘Pharma Bro' Martin Shkreli is publicly accusing Capricor Therapeutics (NASDAQ:CAPR) of fraud and alleging legal action will be taken against its CEO and a consultant over patient data.

3 months ago · globenewswire.com

SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today provided an update ahead of the Company's upcoming FDA Advisory Committee meeting, at which an independent advisory committee will discuss Capricor's Biologics License Application (BLA) for Deramiocel, an investigational cell therapy for the treatment of Duchenne muscular dystrophy (DMD), as part of the FDA's ongoing review of the application.

3 months ago · proactiveinvestors.com

Capricor Therapeutics (NASDAQ:CAPR) shares fell about 67% on Monday after US Food and Drug Administration (FDA) staff reviewers raised concerns about the evidence supporting the effectiveness of the company's experimental cell therapy, deramiocel, for Duchenne muscular dystrophy (DMD)-associated cardiomyopathy. The FDA released briefing documents ahead of a July 29 meeting of its Cellular, Tissue, and Gene Therapies Advisory Committee, which will review the therapy's efficacy and overall risk-benefit profile before the agency's August 22 Prescription Drug User Fee Act (PDUFA) target action date.

3 months ago · benzinga.com

Shares of Capricor Therapeutics Inc. (NASDAQ:CAPR) dropped more than 60% Monday after the FDA posted briefing documents ahead of the company's July 29 advisory committee meeting.

3 months ago · reuters.com

U.S. Food ​and Drug Administration ‌staff reviewers raised ​concerns ​about whether Capricor ⁠Therapeutics' ​cell therapy ​deramiocel has sufficient evidence of ​effectiveness ​for treating cardiomyopathy ‌in ⁠Duchenne muscular dystrophy, according to ​briefing ​documents ⁠released on ​Monday.

4 months ago · benzinga.com

Capricor Therapeutics Inc. (NASDAQ:CAPR) stock is trading lower on Friday, down by 13%.

4 months ago · globenewswire.com

–Advisory Committee meeting scheduled for July 29, 2026– –Company's Biologics License Application on track with PDUFA target action date of August 22, 2026–

5 months ago · newsfilecorp.com

Toronto, Ontario--(Newsfile Corp. - June 19, 2026) - Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Company") is pleased to announce that it has closed its previously announced non-brokered private placement offering of 6,000,000 flow-through shares (the "FT Shares") at a price of $0.10 per FT Share for aggregate gross proceeds of $600,000 (the "Offering"). The Offering was initially announced in the Company's press release dated June 12, 2026.

5 months ago · newsfilecorp.com

Toronto, Ontario--(Newsfile Corp. - June 17, 2026) - Frank Guillemette (the "Acquiror") announces that, on June 12, 2026, he acquired an aggregate of 200,000 common shares in the capital of Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Issuer") through the facilities of the Canadian Securities Exchange for total consideration of $19,136.00 CAD (the "Acquisition"). Immediately prior to the Acquisition, the Acquiror held 20,602,166 common shares and 4,633,333 common share purchase warrants of the Issuer, representing approximately 19.35% of Caprock's issued and outstanding common shares assuming exercise of the common share purchase warrants held by the Acquiror.